A randomized, two-part, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZGN-1061 in healthy normal weight, overweight and obese male and female volunteers
Active, not recruitingNL-OMON42985
Zafgen, Inc.Obesitas
Obesity
Start: 2016-06-30Target: 72Updated: 2024-02-28